239820 CXCR4 Antagonist I, AMD3100 - CAS 155148-31-5 - Calbiochem

239820
Le prix n'a pas pu être récupéré
La quantité minimale doit être un multiple de
À la validation de la commande Plus d'informations
Vous avez sauvegardé ()
 
Demander le prix
Disponibilité limitéeDisponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service
      Voir les Prix & la Disponibilité

      Aperçu

      Replacement Information

      Tableau de caractéristiques principal

      Empirical FormulaCAS #
      C₂₈H₅₄N₈ • 8HCl 155148-31-5

      Prix & Disponibilité

      Référence DisponibilitéConditionnement Qté Prix Quantité
      239820-5MG
      Récupération des données relatives à la disponibilité...
      Disponibilité limitéeDisponibilité limitée
      En stock 
      Interrompu(e)
      Disponible en quantités limitées
      Disponibilité à confirmer
        Pour le restant : Nous vous tiendrons informé
          Pour le restant : Nous vous tiendrons informé
          Nous vous tiendrons informé
          Contacter le Service Clients
          Contact Customer Service

          5 mg
          Prix en cours de récupération
          Le prix n'a pas pu être récupéré
          La quantité minimale doit être un multiple de
          À la validation de la commande Plus d'informations
          Vous avez sauvegardé ()
           
          Demander le prix
          Description
          OverviewA symmetrical bicyclam compound that antagonizes CXCL12 (SDF1) binding to CXCR4 (IC50 = 108 and 245 nM using rat and human CXCR4, respectively) and inhibits SDF1-induced Ca2+ flux (by 100% at 100 ng/ml in SUP-T1 and THP-1 cultures) as well as CXCR4-, but not CCR5-, mediated HIV infection (IC50 ≤200 nM), while enhancing the binding of SDF1 to CXCR7 (by ~60% at 1 mM with CXCR7-expressing HEK293T cells) and SDF1-induced β-arrestin recruitment to CXCR7 (EC50 = 6.48 and 11.8 nM, in the presence and absence of 10 µM AMD3100, respectively). Administration AMD3100 via intravenous infusion is also reported to result in hematopoietic stem cell mobilization in humans, dogs, and mice in vivo. Exhibits no inhibitory effects against chemokine-induced signaling via CXCR1/2/3 or CCR1/2/3/4/5/6/7/8/9. Also available as a 50 mM solution in H2O (Cat. No. 239825).
          Catalogue Number239820
          Brand Family Calbiochem®
          Synonyms1,1ʹ-(1,4-Phenylenebis(methylene))-bis-1,4,8,11-tetraazacyclotetradecane, 8HCl, JM3100
          References
          ReferencesKalatskaya, I., et al. 2009. Mol. Pharmacol. 77, 1240.
          Pitchford, S.C., et al. 2009. Cell Stem Cell 4, 62.
          De Clercq, E. 2009. Biochem. Pharmacol. , 1655.
          Thoma, G., et al. 2008. J. Med. Chem. 51, 7915.
          De Clercq, E. 2000. Mol. Pharmacol. 57, 833.
          Product Information
          CAS number155148-31-5
          FormOff-white solid
          Hill FormulaC₂₈H₅₄N₈ • 8HCl
          Chemical formulaC₂₈H₅₄N₈ • 8HCl
          Hygroscopic Hygroscopic
          Structure formula ImageStructure formula Image
          Quality LevelMQ100
          Applications
          ApplicationCXCR4 Antagonist I, AMD3100, CAS 155148-31-5, is an antagonist of CXCL12 (SDF1) binding to CXCR4 (IC50 = 108 nM for rat CXCR4) and inhibits SDF1-induced Ca2+ flux.
          Biological Information
          Purity≥98% by HPLC
          Physicochemical Information
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Ambient Temperature Only
          Toxicity Standard Handling
          Storage +2°C to +8°C
          Protect from Light Protect from light
          Hygroscopic Hygroscopic
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          CXCR4 Antagonist I, AMD3100 - CAS 155148-31-5 - Calbiochem FDS

          Titre

          Fiche de données de sécurité des matériaux (FDS) 

          CXCR4 Antagonist I, AMD3100 - CAS 155148-31-5 - Calbiochem Certificats d'analyse

          TitreNuméro de lot
          239820

          Références bibliographiques

          Aperçu de la référence bibliographique
          Kalatskaya, I., et al. 2009. Mol. Pharmacol. 77, 1240.
          Pitchford, S.C., et al. 2009. Cell Stem Cell 4, 62.
          De Clercq, E. 2009. Biochem. Pharmacol. , 1655.
          Thoma, G., et al. 2008. J. Med. Chem. 51, 7915.
          De Clercq, E. 2000. Mol. Pharmacol. 57, 833.
          Fiche technique

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision10-March-2010 RFH
          Synonyms1,1ʹ-(1,4-Phenylenebis(methylene))-bis-1,4,8,11-tetraazacyclotetradecane, 8HCl, JM3100
          DescriptionA symmetrical bicyclam compound that antagonizes CXCL12 (SDF1) binding to CXCR4 (IC50 = 108 and 245 nM using rat and human CXCR4, respectively) and inhibits SDF1-induced Ca2+ flux (by 100% at 100 ng/ml in SUP-T1 and THP-1 cultures) as well as CXCR4-, but not CCR5-, mediated HIV infection (IC50 ≤200 nM), while enhancing the binding of SDF1 to CXCR7 (by ~60% at 1 mM with CXCR7-expressing HEK293T cells) and SDF1-induced β-arrestin recruitment to CXCR7 (EC50 = 6.48 and 11.8 nM, in the presence and absence of 10 µM AMD3100, respectively). Administration AMD3100 via intravenous infusion is also reported to result in hematopoietic stem cell mobilization in humans, dogs, and mice in vivo. Exhibits no inhibitory effects against chemokine-induced signaling via CXCR1/2/3 or CCR1/2/3/4/5/6/7/8/9.
          FormOff-white solid
          Intert gas (Yes/No) Packaged under inert gas
          CAS number155148-31-5
          Chemical formulaC₂₈H₅₄N₈ • 8HCl
          Structure formulaStructure formula
          Purity≥98% by HPLC
          SolubilityH₂O (10 mg/ml)
          Storage +2°C to +8°C
          Hygroscopic
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
          Toxicity Standard Handling
          ReferencesKalatskaya, I., et al. 2009. Mol. Pharmacol. 77, 1240.
          Pitchford, S.C., et al. 2009. Cell Stem Cell 4, 62.
          De Clercq, E. 2009. Biochem. Pharmacol. , 1655.
          Thoma, G., et al. 2008. J. Med. Chem. 51, 7915.
          De Clercq, E. 2000. Mol. Pharmacol. 57, 833.